TY - JOUR
T1 - Acute Sirolimus Pulmonary Toxicity in an Infant Heart Transplant Recipient
T2 - Case Report and Literature Review
AU - Das, Bibhuti B.
AU - Shoemaker, Lawrence
AU - Subramanian, Sujata
AU - Johnsrude, Christopher
AU - Recto, Michael
AU - Austin, Erle H.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2007/3
Y1 - 2007/3
N2 - Sirolimus-associated pulmonary disease should be considered in the differential diagnosis of acute respiratory distress syndrome in transplant recipients receiving this drug. It represents a rare, potentially lethal, and yet reversible adverse effect. We report the case an infant who presented with acute respiratory distress 57 days after heart transplantation 3 days after starting sirolimus. The acute presentation and prompt resolution after discontinuation of this drug suggest a direct toxic effect to the lungs. To our knowledge, this is the first published pediatric description of this syndrome after heart transplantation.
AB - Sirolimus-associated pulmonary disease should be considered in the differential diagnosis of acute respiratory distress syndrome in transplant recipients receiving this drug. It represents a rare, potentially lethal, and yet reversible adverse effect. We report the case an infant who presented with acute respiratory distress 57 days after heart transplantation 3 days after starting sirolimus. The acute presentation and prompt resolution after discontinuation of this drug suggest a direct toxic effect to the lungs. To our knowledge, this is the first published pediatric description of this syndrome after heart transplantation.
UR - http://www.scopus.com/inward/record.url?scp=33847391264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847391264&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2006.12.004
DO - 10.1016/j.healun.2006.12.004
M3 - Article
C2 - 17346635
AN - SCOPUS:33847391264
SN - 1053-2498
VL - 26
SP - 296
EP - 298
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 3
ER -